Objective: To compare the efficacy of the gefitinib,erlotinib and icotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. Methods: Clinical data about 76 patients with advanced non-small cell lung cancer in our hospital from May 2013 to December 2014 were retrospectively analyzed. They were randomly divided into gefitinib group,erlotinib group and icotinib group to evaluate the efficacy and safety. Results:There were no significant differences in the objective response r...
【更新日期】
2018-01-12
【分类号】
R734.2
【正文快照】
Modern Oncology 2018,26(02):0216-0219近年来,由于表皮生长因子受体酪氨酸激酶抑制剂(epi-dermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI)确切的疗效、轻微的不良反应和口服给药的便利等特点,突破了传统化疗药物的瓶颈,已经成为晚期非小细胞肺癌(NSCLC)